Hyperattenuating liver: The normal unenhanced attenuation of the liver is 30 to 60 HU. An
absolute attenuation greater than 75 HU is considered hyperattenuating.
Iron overload is by far the most common cause of a hyperattenuating liver.
Medications (e.g., amiodarone, gold, and methotrexate).
Wilson disease (Copper overload).
Glycogen excess.
Hypovascular hepatic metastases include:
Breast.
Pancreas.
Lung.
Lymphoma.
Hypoattenuating liver: The liver is generally considered hypoattenuating if it attenuates less
than the spleen on an unenhanced CT.
Fatty liver (hepatic steatosis) is by far the most common cause of a diffusely hypoattenuating liver.
Hepatic amyloid is rare and may cause either focal or diffuse hepatic hypoattenuation.
Hypervascular hepatic metastases include (mnemonic = MRCT):
Melanoma.
Renal cell carcinoma.
Carcinoid / Choriocarcinoma.
Thyroid.
Calcified hepatic metastases include:
Mucinous cancers (including colon, gastric, ovarian).
Osteosarcoma.
Treated lymphoma.
Cystic hepatic metastases include:
Ovarian cystadenocarcinoma.
Gastrointesti nal sarcoma.
Hepatic capsular retraction
Epithelioid hemangioendothelioma is one cause of capsular retraction.
the diff erenti al of capsular retracti on includes:
Mass-forming cholangiocarcinoma.
Fibrolamellar HCC (seen in 10% of cases of fi brolamellar HCC)
Epithelioid hemangioendothelioma.
Pseudocirrhosis (macronodular liver contour with capsular retracti on due to treated metastases).
Confl uent hepatic fibrosis (wedge-shaped fi brosis that may be seen in cirrhosis).
4 subtypes of hepatic adenomas
Inflammatory: Most common, has the highest bleeding risk.
HNF-alpha 1 mutated: Second most common, characterized by multiple adenomas, associated with FAP
and von Gierke’s.
Beta-catenin mutated: Least common, seen in men on anabolic steroids, has the highest risk of
malignant transformation.
Unclassified.
Multicystic liver lesions
Multiple simple cyst or biliary hamartomas.
Caroli disease (saccular dilation of the intrahepatic bile
ducts).
ADPLD (associated with ADPKD).
VHL.
Hyperenhancing liver lesions
FNH.
Adenoma.
HCC.
Hemangioma (especially flash-filling subtype).
Hypervascular metastases.
Haemorrhagic liver lesions
Adenoma.
HCC.
Metastases
Calcified liver lesions
Mucinous metastases.
Osteosarcoma metastases.
Biliary cystadenoma/cystadenocarcinoma.
Granulomata
Cystic with internal echos liver lesions
Simple cyst with internal hemorrhage or superimposed
infection.
Abscess.
Hematoma.
Necrotic or cystic metastasis.
Fat containing liver lesion
Focal fat.
Adenoma.
HCC.
Angiomyolipoma, lipoma, pseudolipoma of the Glisson’s
capsule (rare).
Central Scar on a liver lesion
FNH.
Fibrolamellar HCC.
Giant hemangioma.
Hepatic capsular retraction
Mass-forming cholangiocarcinoma.
Fibrolamellar HCC.
Epithelioid hemangioendothelioma.
Pseudocirrhosis (treated metastases).
Confluent hepatic fibrosis (wedge-shaped fibrosis that
may be seen in cirrhosis).
Echogenic material within the gallbladder
Gallstone(s) (echogenic, mobile, shadowing).
Gallbladder sludge (echogenic, mobile, non-shadowing).
Gallbladder polyp (echogenic, non-mobile, non-shadowing, oft en att ached to the gallbladder wall via a
stalk, may be vascular).
Hyperplastic cholecystoses (echogenic, non-mobile, multi ple polyps).
Porcelain gallbladder (echogenic wall, shadowing).
Adjacent bowel (echogenic wall, dirty shadowing).
Diffuse gallbladder wall thickening
Protein-wasting nephropathy.
Hepatitis.
Pancreatitis.
Gallbladder carcinoma.
Metastases to gallbladder (rare).
Cholangioca types
Mass forming cholangiocarcinoma.
Periductal cholangiocarcinoma: most oft en at the confl uence of the right and left hepati c biliary ducts
(known as Klatskin tumor).
Intraductal cholangiocarcinoma: has variable imaging appearance.
Risk factors for cholangioca
Risk factors for development of cholangiocarcinoma include:
-Choledochal cyst(s).
-Primary sclerosing cholangiti s.
-Familial adenomatous polyposis syndrome.
-Clonorchis sinensis infecti on.
-Thorium dioxide (alpha-emitt er contrast agent), not used since the 1950s. -Thorium dioxide is also
associated with angiosarcoma and HCC.
Gallstones and chronic cholecysti ti s.
Porcelain gallbladder (somewhat controversial).
Primary sclerosing cholangiti s.
Infl ammatory bowel disease (ulcerati ve coliti s more frequently than Crohn’s disease).
Adenomatous polyp >10 mm or with multi ple risk factors, as described above.
Pancreatic Solid Epithelial Neoplasm
Ductal Adenocarcinoma - 80-90% of pancreatic tumours
Acing cell carcinoma - rare, aggressive can cause fat necrosis
Metastasis
Cystic Epithelial Neoplasms
Serous cystic- benign, many small cysts, elderly woman
Mutinous cystic - malignant potential surgical lesion, single or few large cysts, middle age women
Solid psudopapillary tumour - young women, heterogenous, irone to haemorrhage
Intraductal papillary mutinous neoplasm - malignant potential, elderly males
Pancreatic endocrine neoplasms
Insulinoma - most are benign and small
Gastronome
Glucagonoma
Lipoma
Somatostatinoma
Cystic neuroendocrine tumour
Pancreatic mass with no ductal dilatation
Autoimmune pancreatitis.
Duodenal gastrointestinal stromal tumor (GIST).
Groove pancreatitis.
Peripancreatic lymph node.
Cystic pancreatic tumor.
Pancreatic metastasis (e.g., renal cell, thyroid, or melanoma).
Neuroendocrine tumor.
Lymphoma.